Skip to main content
Top
Published in: Current Treatment Options in Oncology 6/2020

01-06-2020 | Hereditary Syndromes | Neuroendocrine Cancers (JR Strosberg, Section Editor)

Hereditary Syndromes in Neuroendocrine Tumors

Author: Mark A. Lewis, MD

Published in: Current Treatment Options in Oncology | Issue 6/2020

Login to get access

Opinion statement

Oncologists should be able to discern the salient clinical features of the most common germline mutations that give rise to neuroendocrine tumors. Astute recognition of an index patient affected by a hereditary syndrome can lead to a “tip-of-the-iceberg” phenomenon whereby their entire kindred can then be proactively monitored and managed potentially with substantial reduction of morbidity and mortality. Through careful history-taking, as well as thoughtful assimilation of findings from the physical exam, biochemical laboratories, scans, and pathology reports, the clinician can spot phenotypic clues that distinguish these familial patterns from sporadic cases of tumorigenesis.
Literature
1.
go back to reference Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987;5(10):1502–22.PubMedCrossRef Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987;5(10):1502–22.PubMedCrossRef
2.
go back to reference Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990.PubMedCrossRef Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990.PubMedCrossRef
3.
go back to reference de Laat JM, Dekkers OM, Pieterman CR, Kluijfhout WP, Hermus AR, Pereira AM, et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG). J Clin Endocrinol Metab. 2015;100(9):3288.PubMedCrossRef de Laat JM, Dekkers OM, Pieterman CR, Kluijfhout WP, Hermus AR, Pereira AM, et al. Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG). J Clin Endocrinol Metab. 2015;100(9):3288.PubMedCrossRef
4.
go back to reference Conemans EB, Nell S, Pieterman CRC, de Herder WW, Dekkers OM, Hermus AR, et al. Prognostic factors for survival of MEN1 patients with duodenopancreatic tumors metastatic to the liver: results from the DSMG. Endocr Pract. 2017;23(6):641–8.PubMedCrossRef Conemans EB, Nell S, Pieterman CRC, de Herder WW, Dekkers OM, Hermus AR, et al. Prognostic factors for survival of MEN1 patients with duodenopancreatic tumors metastatic to the liver: results from the DSMG. Endocr Pract. 2017;23(6):641–8.PubMedCrossRef
5.
go back to reference Pieterman CRC, de Laat JM, Twisk JWR, van Leeuwaarde RS, de Herder WW, Dreijerink KMA, et al. Long-term natural course of small nonfunctional pancreatic neuroendocrine tumors in MEN1-results from the Dutch MEN1 study group. J Clin Endocrinol Metab. 2017;102(10):3795–805.CrossRefPubMed Pieterman CRC, de Laat JM, Twisk JWR, van Leeuwaarde RS, de Herder WW, Dreijerink KMA, et al. Long-term natural course of small nonfunctional pancreatic neuroendocrine tumors in MEN1-results from the Dutch MEN1 study group. J Clin Endocrinol Metab. 2017;102(10):3795–805.CrossRefPubMed
6.
go back to reference Asgharian B, Turner ML, Gibril F, Entsuah LK, Serrano J, Jensen RT. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab. 2004;89(11):5328–36.PubMedCrossRef Asgharian B, Turner ML, Gibril F, Entsuah LK, Serrano J, Jensen RT. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab. 2004;89(11):5328–36.PubMedCrossRef
7.
go back to reference Ventura M, Melo M, Carrilho F. Outcome and long-term follow-up of adrenal lesions in multiple endocrine neoplasia type 1. Arch Endocrinol Metab. 2019;63(5):516–23.PubMed Ventura M, Melo M, Carrilho F. Outcome and long-term follow-up of adrenal lesions in multiple endocrine neoplasia type 1. Arch Endocrinol Metab. 2019;63(5):516–23.PubMed
8.
go back to reference Christakis I, Qiu W, Silva Figueroa AM, Hyde S, Cote GJ, Busaidy NL, et al. Clinical features, treatments, and outcomes of patients with thymic carcinoids and multiple endocrine neoplasia type 1 syndrome at MD Anderson Cancer Center. Horm Cancer. 2016;7(4):279–87.PubMedCrossRef Christakis I, Qiu W, Silva Figueroa AM, Hyde S, Cote GJ, Busaidy NL, et al. Clinical features, treatments, and outcomes of patients with thymic carcinoids and multiple endocrine neoplasia type 1 syndrome at MD Anderson Cancer Center. Horm Cancer. 2016;7(4):279–87.PubMedCrossRef
9.
go back to reference Frilling A, Weber F, Tecklenborg C, Broelsch CE. Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene. Langenbeck’s Arch Surg. 2003;388(1):17–26.CrossRef Frilling A, Weber F, Tecklenborg C, Broelsch CE. Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene. Langenbeck’s Arch Surg. 2003;388(1):17–26.CrossRef
10.
go back to reference • Frederiksen A, Rossing M, Hermann P, Ejersted C, Thakker RV, Frost M. Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases. J Clin Endocrinol Metab. 2019;104(9):3637–46 A recent review of cases of MEN4 clarifying its clinical phenotype, especially compared to MEN1.PubMedPubMedCentralCrossRef • Frederiksen A, Rossing M, Hermann P, Ejersted C, Thakker RV, Frost M. Clinical features of multiple endocrine neoplasia type 4: novel pathogenic variant and review of published cases. J Clin Endocrinol Metab. 2019;104(9):3637–46 A recent review of cases of MEN4 clarifying its clinical phenotype, especially compared to MEN1.PubMedPubMedCentralCrossRef
12.
go back to reference van Leeuwaarde RS, Ahmad S, Links TP, et al. Von Hippel-Lindau syndrome. 2000 May 17 [Updated 2018 Sep 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1463/. Accessed 13 Jan 2020. van Leeuwaarde RS, Ahmad S, Links TP, et al. Von Hippel-Lindau syndrome. 2000 May 17 [Updated 2018 Sep 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020. Available from: https://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK1463/​. Accessed 13 Jan 2020.
13.
go back to reference Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150(5):681–6.PubMedCrossRef Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150(5):681–6.PubMedCrossRef
14.
go back to reference Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61.PubMedCrossRef Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61.PubMedCrossRef
15.
go back to reference Bayley JP, Oldenburg RA, Nuk J, Hoekstra AS, van der Meer CA, Korpershoek E, et al. Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. BMC Med Genet. 2014;15:111.PubMedPubMedCentralCrossRef Bayley JP, Oldenburg RA, Nuk J, Hoekstra AS, van der Meer CA, Korpershoek E, et al. Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. BMC Med Genet. 2014;15:111.PubMedPubMedCentralCrossRef
16.
go back to reference HC MC, Babajanian E, Calquin M, Carpenter P, Casazza G, Naumer A, et al. Characterization of malignant head and neck paragangliomas at a single institution across multiple decades. JAMA Otolaryngol Head Neck Surg. 2019;145(7):641–6.CrossRef HC MC, Babajanian E, Calquin M, Carpenter P, Casazza G, Naumer A, et al. Characterization of malignant head and neck paragangliomas at a single institution across multiple decades. JAMA Otolaryngol Head Neck Surg. 2019;145(7):641–6.CrossRef
17.
go back to reference Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.PubMedCrossRef Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42.PubMedCrossRef
18.
go back to reference Jasim S, Jimenez C. Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. Best Pract Res Clin Endocrinol Metab. 2019;24:101354.CrossRef Jasim S, Jimenez C. Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. Best Pract Res Clin Endocrinol Metab. 2019;24:101354.CrossRef
20.
go back to reference Griffiths DF, Williams GT, Williams ED. Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: islet cell tumour, phaeochromocytoma and the von Hippel-Lindau complex: two distinctive neuroendocrine syndromes. Q J Med. 1987;64(245):769–82.PubMed Griffiths DF, Williams GT, Williams ED. Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: islet cell tumour, phaeochromocytoma and the von Hippel-Lindau complex: two distinctive neuroendocrine syndromes. Q J Med. 1987;64(245):769–82.PubMed
21.
go back to reference Vaassen P, Dürr N, Röhrig A, Willing R, Rosenbaum T. Trametinib induces neurofibroma shrinkage and enables surgery. Neuropediatrics. 2019;50(5):300–3.PubMedCrossRef Vaassen P, Dürr N, Röhrig A, Willing R, Rosenbaum T. Trametinib induces neurofibroma shrinkage and enables surgery. Neuropediatrics. 2019;50(5):300–3.PubMedCrossRef
22.
go back to reference Kurlemann G, Schuierer G. Images in clinical medicine. Ash-leaf spots in tuberous sclerosis. N Engl J Med. 1998;338(26):1887.PubMedCrossRef Kurlemann G, Schuierer G. Images in clinical medicine. Ash-leaf spots in tuberous sclerosis. N Engl J Med. 1998;338(26):1887.PubMedCrossRef
23.
go back to reference Bongiorno MA, Nathan N, Oyerinde O, Wang JA, Lee CR, Brown GT, et al. Clinical characteristics of connective tissue nevi in tuberous sclerosis complex with special emphasis on shagreen patches. JAMA Dermatol. 2017;153(7):660–5.PubMedPubMedCentralCrossRef Bongiorno MA, Nathan N, Oyerinde O, Wang JA, Lee CR, Brown GT, et al. Clinical characteristics of connective tissue nevi in tuberous sclerosis complex with special emphasis on shagreen patches. JAMA Dermatol. 2017;153(7):660–5.PubMedPubMedCentralCrossRef
24.
go back to reference Larson AM, Hedgire SS, Deshpande V, Stemmer-Rachamimov AO, Harisinghani MG, Ferrone CR, et al. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet. 2012;82(6):558–63.PubMedCrossRef Larson AM, Hedgire SS, Deshpande V, Stemmer-Rachamimov AO, Harisinghani MG, Ferrone CR, et al. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet. 2012;82(6):558–63.PubMedCrossRef
25.
go back to reference Joinson C, O’Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med. 2003;33(2):335–44.PubMedCrossRef Joinson C, O’Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med. 2003;33(2):335–44.PubMedCrossRef
26.
go back to reference Nuñez JE, Donadio M, Filho DR, Rego JF, Barros M, Formiga MN, et al. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2019;10(4):645–51.PubMedPubMedCentralCrossRef Nuñez JE, Donadio M, Filho DR, Rego JF, Barros M, Formiga MN, et al. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2019;10(4):645–51.PubMedPubMedCentralCrossRef
27.
go back to reference Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, et al. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018;19:1351–9.PubMedPubMedCentralCrossRef Jonasch E, McCutcheon IE, Gombos DS, Ahrar K, Perrier ND, Liu D, et al. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 2018;19:1351–9.PubMedPubMedCentralCrossRef
28.
go back to reference Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–21.PubMedPubMedCentralCrossRef Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–21.PubMedPubMedCentralCrossRef
29.
go back to reference Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.PubMedCrossRef Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.PubMedCrossRef
30.
go back to reference •• Tan ZY, Huang T, Ngeow J. 65 YEARS OF THE DOUBLE HELIX: the advancements of gene editing and potential application to hereditary cancer. Endocr Relat Cancer. 2018;25(8):T141–58 Superb synopsis of CRISPR-CAS9’s addition to the genome editing toolbox and the rationale for its use against hereditary cancer predisposition syndromes.PubMedCrossRef •• Tan ZY, Huang T, Ngeow J. 65 YEARS OF THE DOUBLE HELIX: the advancements of gene editing and potential application to hereditary cancer. Endocr Relat Cancer. 2018;25(8):T141–58 Superb synopsis of CRISPR-CAS9’s addition to the genome editing toolbox and the rationale for its use against hereditary cancer predisposition syndromes.PubMedCrossRef
31.
go back to reference •• Kofler N, Kraschel KL. Treatment of heritable diseases using CRISPR: hopes, fears, and reality. Semin Perinatol. 2018;42(8):515–21 Contemporaneous review article that frames CRISPR’s potential therapeutic applications within the current regulatory landscape.PubMedCrossRef •• Kofler N, Kraschel KL. Treatment of heritable diseases using CRISPR: hopes, fears, and reality. Semin Perinatol. 2018;42(8):515–21 Contemporaneous review article that frames CRISPR’s potential therapeutic applications within the current regulatory landscape.PubMedCrossRef
33.
go back to reference Wasserman JD, Tomlinson GE, Druker H, Kamihara J, Kohlmann WK, Kratz CP, et al. Multiple endocrine neoplasia and hyperparathyroid-jaw tumor syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res. 2017;23(13):e123–32.PubMedPubMedCentralCrossRef Wasserman JD, Tomlinson GE, Druker H, Kamihara J, Kohlmann WK, Kratz CP, et al. Multiple endocrine neoplasia and hyperparathyroid-jaw tumor syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res. 2017;23(13):e123–32.PubMedPubMedCentralCrossRef
34.
go back to reference Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N, et al. Pheochromocytoma screening initiation and frequency in von Hippel-Lindau syndrome. J Clin Endocrinol Metab. 2015;100(12):4498–504.PubMedPubMedCentralCrossRef Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N, et al. Pheochromocytoma screening initiation and frequency in von Hippel-Lindau syndrome. J Clin Endocrinol Metab. 2015;100(12):4498–504.PubMedPubMedCentralCrossRef
36.
go back to reference Hersh JH, American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics. 2008;121(3):633–42.PubMedCrossRef Hersh JH, American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics. 2008;121(3):633–42.PubMedCrossRef
37.
go back to reference Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255–65.PubMedPubMedCentralCrossRef Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):255–65.PubMedPubMedCentralCrossRef
38.
go back to reference Quinn G, Vadaparampil S, Wilson C, King L, Choi J, Miree C, et al. Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril. 2009;91(6):2361–8.PubMedCrossRef Quinn G, Vadaparampil S, Wilson C, King L, Choi J, Miree C, et al. Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertil Steril. 2009;91(6):2361–8.PubMedCrossRef
39.
go back to reference Handyside AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature. 1990;344(6268):768–70.PubMedCrossRef Handyside AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature. 1990;344(6268):768–70.PubMedCrossRef
40.
go back to reference Handyside AH, Xu K. Preimplantation genetic diagnosis comes of age. Semin Reprod Med. 2012;30(4):255–8.PubMedCrossRef Handyside AH, Xu K. Preimplantation genetic diagnosis comes of age. Semin Reprod Med. 2012;30(4):255–8.PubMedCrossRef
41.
go back to reference Yeager S, Mehta S, Sodhi M, Shah B. Can preimplantation genetic diagnosis be used for monogenic endocrine diseases? J Pediatr Endocrinol Metab. 2019;32(12):1305–10.PubMedCrossRef Yeager S, Mehta S, Sodhi M, Shah B. Can preimplantation genetic diagnosis be used for monogenic endocrine diseases? J Pediatr Endocrinol Metab. 2019;32(12):1305–10.PubMedCrossRef
42.
go back to reference Lima AD, Alves VR, Rocha AR, Martinhago AC, Martinhago C, Donadio N, et al. Preimplantation genetic diagnosis for a patient with multiple endocrine neoplasia type 1: case report. JBRA Assist Reprod. 2018;22(1):67–70.PubMedPubMedCentral Lima AD, Alves VR, Rocha AR, Martinhago AC, Martinhago C, Donadio N, et al. Preimplantation genetic diagnosis for a patient with multiple endocrine neoplasia type 1: case report. JBRA Assist Reprod. 2018;22(1):67–70.PubMedPubMedCentral
43.
go back to reference Chen S, Li S, Zhang J, Zhang L, Chen Y, Wang L, et al. Preimplantation genetic diagnosis of multiple endocrine Neoplasia type 2A using informative markers identified by targeted sequencing. Thyroid. 2018;28(3):281–7.PubMedCrossRef Chen S, Li S, Zhang J, Zhang L, Chen Y, Wang L, et al. Preimplantation genetic diagnosis of multiple endocrine Neoplasia type 2A using informative markers identified by targeted sequencing. Thyroid. 2018;28(3):281–7.PubMedCrossRef
44.
go back to reference Obradors A, Fernández E, Rius M, Oliver-Bonet M, Martínez-Fresno M, Benet J, et al. Outcome of twin babies free of Von Hippel-Lindau disease after a double-factor preimplantation genetic diagnosis: monogenetic mutation analysis and comprehensive aneuploidy screening. Fertil Steril. 2009;91(3):933.e1–7.CrossRef Obradors A, Fernández E, Rius M, Oliver-Bonet M, Martínez-Fresno M, Benet J, et al. Outcome of twin babies free of Von Hippel-Lindau disease after a double-factor preimplantation genetic diagnosis: monogenetic mutation analysis and comprehensive aneuploidy screening. Fertil Steril. 2009;91(3):933.e1–7.CrossRef
45.
go back to reference Merker VL, Murphy TP, Hughes JB, Muzikansky A, Hughes MR, Souter I, et al. Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. Fertil Steril. 2015;103(3):761–8.e1.PubMedCrossRef Merker VL, Murphy TP, Hughes JB, Muzikansky A, Hughes MR, Souter I, et al. Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. Fertil Steril. 2015;103(3):761–8.e1.PubMedCrossRef
46.
go back to reference Naja RP, Dhanjal S, Doshi A, Serhal P, Delhanty J, SB SG. The impact of mosaicism in preimplantation genetic diagnosis (PGD): approaches to PGD for dominant disorders in couples without family history. Prenat Diagn. 2016;36(9):864–70.PubMedCrossRef Naja RP, Dhanjal S, Doshi A, Serhal P, Delhanty J, SB SG. The impact of mosaicism in preimplantation genetic diagnosis (PGD): approaches to PGD for dominant disorders in couples without family history. Prenat Diagn. 2016;36(9):864–70.PubMedCrossRef
Metadata
Title
Hereditary Syndromes in Neuroendocrine Tumors
Author
Mark A. Lewis, MD
Publication date
01-06-2020
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 6/2020
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-020-00749-5

Other articles of this Issue 6/2020

Current Treatment Options in Oncology 6/2020 Go to the issue

Neuroendocrine Cancers (JR Strosberg, Section Editor)

Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms

Skin Cancer (T Ito, Section Editor)

Current Treatment of Melanoma Brain Metastasis

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine